First Time Loading...

InflaRx NV
NASDAQ:IFRX

Watchlist Manager
InflaRx NV Logo
InflaRx NV
NASDAQ:IFRX
Watchlist
Price: 1.24 USD -4.25% Market Closed
Updated: May 8, 2024

Relative Value

The Relative Value of one IFRX stock under the Base Case scenario is 5.64 USD. Compared to the current market price of 1.24 USD, InflaRx NV is Undervalued by 78%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

IFRX Relative Value
Base Case
5.64 USD
Undervaluation 78%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
12
vs Industry
4
Median 3Y
0
Median 5Y
0
Industry
8.3
Forward
15.5
vs History
vs Industry
Median 3Y
-3
Median 5Y
-2.7
Industry
26.8
Forward
-1.3
vs History
vs Industry
Median 3Y
-2.7
Median 5Y
-2.7
Industry
23.3
vs History
vs Industry
Median 3Y
-2.6
Median 5Y
-2.6
Industry
21.4
vs History
84
vs Industry
69
Median 3Y
1
Median 5Y
1
Industry
2.6
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
7.5
Forward
-4.1
vs History
3
vs Industry
16
Median 3Y
0
Median 5Y
0
Industry
9.2
vs History
11
vs Industry
20
Median 3Y
-0.1
Median 5Y
-0.4
Industry
4.5
Forward
3.7
vs History
11
vs Industry
19
Median 3Y
-0.1
Median 5Y
-0.4
Industry
4.4
Forward
0.3
vs History
11
vs Industry
21
Median 3Y
-0.2
Median 5Y
-0.4
Industry
5.6
vs History
11
vs Industry
18
Median 3Y
-0.2
Median 5Y
-0.4
Industry
3.4
vs History
vs Industry
69
Median 3Y
1
Median 5Y
0.6
Industry
5

Multiples Across Competitors

IFRX Competitors Multiples
InflaRx NV Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
DE
InflaRx NV
NASDAQ:IFRX
76m USD 1 076.2 -1.6 0.4 0.4
US
Abbvie Inc
NYSE:ABBV
286.9B USD 5.3 59.5 12.9 19.7
US
Amgen Inc
NASDAQ:AMGN
161B USD 5.5 42.8 18.2 30
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
105.9B USD 10.7 29.2 23.5 24.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
106.1B USD 8.1 27.5 22.2 24.7
AU
CSL Ltd
ASX:CSL
135.1B AUD 6.3 36 21.8 27
US
Gilead Sciences Inc
NASDAQ:GILD
81.9B USD 3 169.3 6.8 8.9
US
Moderna Inc
NASDAQ:MRNA
45.7B USD 8.9 -7.7 -8.3 -7.3
US
Seagen Inc
NASDAQ:SGEN
43.1B USD 18.8 -57.5 -61.9 -55.8
US
Biogen Inc
NASDAQ:BIIB
31.6B USD 3.3 27.1 13.9 17.3
KR
Celltrion Inc
KRX:068270
40.3T KRW 18.5 75.2 46 63.3
P/E Multiple
Earnings Growth
DE
InflaRx NV
NASDAQ:IFRX
Average P/E: 58.3
Negative Multiple: -1.6
N/A
US
Abbvie Inc
NYSE:ABBV
59.5
405%
US
Amgen Inc
NASDAQ:AMGN
42.8
82%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
29.2
49%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
27.5
45%
AU
CSL Ltd
ASX:CSL
36
84%
US
Gilead Sciences Inc
NASDAQ:GILD
169.3
75%
US
Moderna Inc
NASDAQ:MRNA
Negative Multiple: -7.7 N/A
US
Seagen Inc
NASDAQ:SGEN
Negative Multiple: -57.5 N/A
US
Biogen Inc
NASDAQ:BIIB
27.1
155%
KR
Celltrion Inc
KRX:068270
75.2
105%

See Also

Discover More